Toxicity and Efficacy of Isolated Lung Perfusion with Gemcitabine in a Rat Model of Pulmonary Metastases

Abstract

Background: Long-term toxicity and efficacy of isolated left lung perfusion (ILuP) with gemcitabine (GCB) were studied in a rat model of metastatic pulmonary adenocarcinoma. Materials: Toxicity: Forty rats were randomized into six groups and administered 160 or 320 mg/kg GCB or buffered starch, received either via intravenous injection (IV) or via ILuP. Efficacy experiment: Rats with unilateral metastases had ILuP with 320 mg/kg GCB (maximally tolerated dose administered by ILuP), while rats with bilateral metastases had an IV injection of 160 mg/kg GCB (maximally tolerated dose given by IV). Results: Toxicity experiment: After IV treatments, all rats receiving 320 mg/kg GCB died within one week, while rats who had received 160 mg/kg GCB had a survival rate of 60 %. After ILuP with 160 mg/kg GCB and 320 mg/kg GCB, survival rates were 83 % in both groups. A significant increase in collagen deposits was observed for ILuP with 320 mg/kg GCB compared to rats treated IV with 160 mg/kg GCB. Efficacy experiment: Median survival of ILuP rats treated with 320 mg/kg (38 ± 4 days) was significantly longer compared to IV rats treated with 160 mg/kg (27 ± 2 days; p = 0.02). Conclusions: ILuP with GCB prolongs survival in experimental metastatic adenocarcinoma while no major acute or long term toxicity is observed.

Gemcitabine - isolated lung perfusion - pulmonary toxicity - lung metastases

References

• 1 Jemel A, Tiwari R C, Murray T. et al . Cancer statistics.  Ca Cancer J Clin. 2004;  1 8-29
• 2 Pastorino U, Buyse M, Friedel G. et al . Long-term results of lung metastasectomy: prognostic analysis based on 5206 cases.  J Thorac Cardiovasc Surg. 1997;  113 37-49
• 3 Lanza L A, Putnam J B, Benjamin R S, Roth J A. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases.  Ann Thorac Surg. 1991;  51 219-224
• 4 Nawata S, Abecasis N, Ross H. et al . Isolated lung perfusion with melphalan for the treatment of metastatic sarcoma.  J Thorac Cardiovasc Surg. 1996;  112 1542-1548
• 5 Hendriks J MH, Van Schil P EY, De Boeck G. et al . Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma.  Ann Thorac Surg. 1998;  66 1719-1725
• 6 Hendriks J MH, Van Schil P EY, Van Oosterom A AT, Kuppen P JK, Van Marck E, Eyskens E. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma.  Eur Surg Res. 1999;  31 267-271
• 7 Kornmann M, Butzer U, Blatter J, Beger H G, Link K H. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.  Eur J Surg Oncol. 2000;  26 583-587
• 8 Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J. Advanced breast cancer: a phase II trial with gemcitabine.  J Clin Oncol. 1995;  13 2731-2736
• 9 Van Putte B P, Hendriks J MH, Romijn S, Guetens G, De Bruijn E, Van Schil P EY. Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.  J Surg Res. 2003;  109 118-122
• 10 Van Putte B P, Hendriks J MH, Romijn S, Guentens G, De Bruijn E A, Van Schil P EY. Single-pass isolated lung perfusion versus recirculating isolated lung perfusion with melphalan in a rat model.  Ann Thorac Surg. 2002;  74 893-898
• 11 Van Putte B P, Romijn S, Hendriks J MH, De Bruijn E A, Van Schil P EY. Pharmacokinetics after pulmonary artery perfusion with gemcitabine.  Ann Thorac Surg. 2003;  76 1036-1040
• 12 Marquet R L, Westbroek D L, Jekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site.  Int J Cancer. 1984;  33 689-692
• 13 Weksler B, Schneider A, Ng B, Burt M. Isolated single-lung perfusion in the rat: an experimental model.  J Appl Physiol. 1993;  74 2736-2739
• 14 Abolhoda A, Brooks A, Nawata S, Kneda Y, Cheng H, Burt M E. Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases.  Ann Thorac Surg. 1997;  64 181-184
• 15 Port J L, Ng B, Ellis J L, Nawata S, Lenert J T, Burt M E. Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.  Ann Thorac Surg. 1996;  62 848-852
• 16 Tanaka T, Kaneda Y, Li T, Matsuoka T, Zempo N, Esato K. Digitonin enhances the antitumor effect of cisplatinum during isolated lung perfusion.  Ann Thorac Surg. 2001;  72 1173-1178
• 17 De Pas T, Curigliano G, Franceschielli L, Catania C, Spaggiari L, De Braud F. Gemcitabine-induced systemic capillary leak syndrome.  Ann Oncol. 2001;  12 1651-1652
• 18 Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrota B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature.  Am J Clin Oncol. 2002;  25 96-100
• 19 Pavlakis N, Bell D R, Millward M J, Levi J A. Fatal pulmonary toxicity resulting from treatment with gemcitabine.  Cancer. 1997;  80 286-291
• 20 Rosado M F, Kett D H, Schein R M, Baraona F J, Sridhar K S. Severe pulmonary toxicity in a patient treated with gemcitabine.  Am J Clin Oncol. 2002;  25 31-33
• 21 Ueda K, Sugi K, Li T S, Saeki K, Nawata S, Esato K. The long-term evaluation of pulmonary toxicity following isolated lung perfusion with melphalan in the rat.  Anticancer Res. 1999;  19 141-148
• 22 Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine.  Anticancer drugs. 1995;  6 (Suppl 6) 7-13
• 23 Van Moorsel C JA, Veerman G, Bergman A M. et al . Combination chemotherapy studies with gemcitabine.  Semin Oncol. 1997;  24 (Suppl 2) S7-17-S7-23